HTRA2 Recombinant Antibody

$Western blot analysis of Jurkat cell lysate. Using HTRA2 (bsm-61230R) monoclonal antibody at 1:1000 dilution and 4\u00b0C overnight incubation. Followed by conjugated secondary antibody incubation at r.t. for 60 min.\r\n$

Western blot analysis of Jurkat cell lysate. Using HTRA2 (bsm-61230R) monoclonal antibody at 1:1000 dilution and 4\u00b0C overnight incubation. Followed by conjugated secondary antibody incubation at r.t. for 60 min.\r\n

Applications

WB
IHC-P
IHC-F
IP
IF

Reactivity

Human
Mouse
Rat

Overview
Catalog #	bsm-61230r
Product Name	HTRA2 Recombinant Antibody
Applications	WB, IHC-P, IHC-F, IP, IF
Reactivity	Human, Mouse, Rat
Specifications
Conjugation	Unconjugated
Host	Rabbit
Source	KLH conjugated synthetic peptide derived from human HTRA2
Clonality	Recombinant
Isotype	IgG
Concentration	Lot dependent
Purification	Purified by Protein A.
Storage Buffer	0.01M TBS (pH 7.4), 1% BSA, 0.02% Proclin 300, and 50% Glycerol
Storage Condition	Shipped at 4C. Store at -20C for one year. Avoid repeated freeze/thaw cycles.
Target
Gene ID	27429
Swiss Prot	O43464
Subcellular location	Cytoplasm, Cell membrane
Synonyms	HTRA2; HtrA-like serine protease; OMI; PARK13; Protease; PRSS25; Serine protease 25; HtrA serine peptidase 2; Serine proteinase OMI.
Background	Serine protease that shows proteolytic activity against a non-specific substrate beta-casein. Promotes or induces cell death either by direct binding to and inhibition of BIRC proteins (also called inhibitor of apoptosis proteins, IAPs), leading to an increase in caspase activity, or by a BIRC inhibition-independent, caspase-independent and serine protease activity-dependent mechanism. Cleaves THAP5 and promotes its degradation during apoptosis. Isoform 2 seems to be proteolytically inactive.
Application Dilution
WB	1:300-5000
IHC-P	1:200-400
IHC-F	1:100-500
IP	1-2ug
IF